Biotech News

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics (ARQT)Arcutis Biotherapeutics2026-06-25 13:46 ESTClinical readout

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four

Open original release

Related news

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

ARQTArcutis Biotherapeutics2026-06-25 13:46 EST

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

View all latest news

Arcutis Biotherapeutics

Arcutis Biotherapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ARQTArcutis Biotherapeutics2026-06-26 09:56 EST

New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

ARQTArcutis Biotherapeutics2026-06-26 09:56 EST

Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

ARQTArcutis Biotherapeutics2026-06-26 09:56 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-06-26 09:56 EST

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-06-26 09:56 EST

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States